Thymosin Alpha-1: Complete Guide

Thymosin alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland. It plays a central role in how your immune system matures, activates, and responds to threats. Unlike many peptides in the peptide therapy space that are still in early research phases, Tα1 has decades of clinical data behind it — and it’s approved as a prescription drug in over 35 countries under the brand name Zadaxin [1].

Its story in the U.S. is more complicated. The FDA granted it orphan drug status for several conditions but never approved it for general use. After being caught up in the 2024 compounding restrictions, thymosin alpha-1 was recently reclassified back to Category 1, making it available again through compounding pharmacies. For a full rundown of which peptides are available and which aren’t, check our complete list of peptides.

Key Takeaways

Thymosin alpha-1 is approved in 35+ countries as the drug Zadaxin for hepatitis B, hepatitis C, and immune deficiency conditions
It modulates immunity by activating dendritic cells, T-cells, and natural killer cells — enhancing the body’s own defenses rather than suppressing them
Standard dosing is 1.6 mg subcutaneous injection twice per week, based on the Zadaxin protocol used in clinical trials
The FDA reclassified Tα1 back to Category 1 in early 2026, restoring access through 503A compounding pharmacies

What Is Thymosin Alpha-1?
How Thymosin Alpha-1 Works
Clinical Evidence
Thymosin Alpha-1 Dosing
Side Effects and Safety
Legal and Regulatory Status
Thymosin Alpha-1 vs Other Immune Peptides
FAQ
Sources

What Is Thymosin Alpha-1?

The thymus gland sits behind your sternum and serves as a training ground for immune cells. It’s most active during childhood and adolescence, then gradually shrinks — a process called thymic involution. By age 50, much of the thymus has been replaced by fatty tissue, which is one reason immune function declines with age [2].

Thymosin alpha-1 was first isolated from thymus tissue by Allan Goldstein at the George Washington University School of Medicine in the 1970s. His team identified it as one of the key signaling molecules the thymus uses to program immature T-cells into functional immune warriors [1].

The synthetic version, thymalfasin, is identical to the naturally occurring peptide. It was developed by SciClone Pharmaceuticals and commercialized as Zadaxin. Today it’s one of the most widely prescribed immune-modulating peptides worldwide, though its availability varies significantly by country [3].

How Thymosin Alpha-1 Works

Tα1 doesn’t work like a stimulant that simply “boosts” your immune system. It acts as a modulator — increasing immune activity when it’s suppressed and helping regulate it when it’s overactive. This bidirectional effect is what makes it particularly interesting for clinical use [1][4].

Here’s what the research shows it does:

Dendritic cell activation. Tα1 stimulates dendritic cells, which are the immune system’s scouts. These cells capture foreign antigens and present them to T-cells, effectively telling the adaptive immune system what to attack. Tα1 increases dendritic cell maturation through Toll-like receptor signaling pathways [4].

T-cell differentiation. The peptide promotes the differentiation of CD4+ and CD8+ T-cells from precursor cells. CD4+ cells coordinate immune responses. CD8+ cells directly kill infected or abnormal cells. Tα1 also increases T-cell production of interleukin-2 (IL-2) and interferon-alpha (IFN-α), two cytokines that amplify immune responses [1][5].

Natural killer cell enhancement. NK cells are your first line of defense against virally infected cells and tumor cells. Tα1 increases both the number and activity of NK cells [5].

Anti-inflammatory balance. Despite activating immune cells, Tα1 also promotes regulatory T-cell activity, which helps prevent the immune system from overshooting and causing autoimmune damage. This is why it’s been studied in conditions involving both immune suppression and immune dysregulation [4].

For more on how peptides interact with your body at a molecular level, see how do peptides work.

Clinical Evidence

Hepatitis B

This is where Tα1 has the strongest clinical track record. Multiple randomized controlled trials have evaluated thymalfasin for chronic hepatitis B, both as monotherapy and in combination with interferon-alpha.

A pivotal trial published in Hepatology showed that Tα1 monotherapy (1.6 mg SC twice weekly for 6 months) achieved sustained virological response rates of 36.4% at 12 months follow-up, compared to 18.8% in the placebo group [6]. A meta-analysis of 8 randomized trials including 759 patients confirmed that Tα1, alone or combined with interferon, significantly improved virological and biochemical response rates over placebo or interferon alone [7].

These results led to Zadaxin’s approval for hepatitis B treatment across Asia, Latin America, Eastern Europe, and the Middle East — more than 35 countries in total [3].

Hepatitis C

Combination therapy using Tα1 with interferon-alpha and ribavirin showed improved sustained virological response rates in hepatitis C patients who had failed prior interferon treatment. One study reported SVR rates of 48% in the triple-therapy group versus 24% with interferon and ribavirin alone [8]. While newer direct-acting antivirals have largely replaced this approach for hepatitis C, the data demonstrated Tα1’s ability to enhance antiviral immunity.

Cancer Immunotherapy

Tα1 has been studied as an adjunct to chemotherapy in several cancer types. The FDA granted orphan drug designation for hepatocellular carcinoma and malignant melanoma [1].

A meta-analysis of 26 randomized trials involving over 2,700 patients found that adding Tα1 to chemotherapy improved overall survival, objective response rates, and quality of life compared to chemotherapy alone, particularly in non-small cell lung cancer and hepatocellular carcinoma [9]. The mechanism appears to be restoration of immune function that chemotherapy suppresses.

Immune Deficiency and Infection

Tα1 has shown benefit in several immune-compromised populations:

Sepsis: A meta-analysis of 19 randomized trials (2,616 patients) found that Tα1 reduced 28-day mortality by 16% in severe sepsis patients when added to standard care [10].
Post-surgical immune recovery: Multiple trials showed faster recovery of immune markers after major surgery with Tα1 administration [5].
DiGeorge syndrome: The FDA granted orphan drug status for this congenital immune deficiency, where patients are born with absent or underdeveloped thymus tissue [1].

COVID-19

During the pandemic, several studies evaluated Tα1 for COVID-19. Results were mixed. A retrospective study of 76 severe COVID patients in China found that Tα1 treatment was associated with reduced mortality (11.1% vs 30.0%) and faster lymphocyte recovery [11]. However, a larger randomized trial did not confirm a statistically significant mortality benefit, though it did show improved immune cell counts [12].

Thymosin Alpha-1 Dosing

The standard clinical dosing protocol, established through the Zadaxin trials and used across most clinical applications, is straightforward:

Standard protocol: 1.6 mg administered subcutaneously, twice per week (typically Monday and Thursday or Tuesday and Friday), for a treatment course of 6 months [6][7].

Some clinicians use modified protocols:

Maintenance dosing: 1.6 mg once weekly after an initial loading phase
Acute immune support: 1.6 mg daily for 7–14 days, then transitioning to twice weekly
Cancer adjunct: 1.6 mg twice weekly, timed around chemotherapy cycles (typically started 3 days before each cycle)

The 1.6 mg dose is based on the commercially produced Zadaxin formulation. Compounded versions may vary slightly in concentration, but the target dose remains the same. Injections are typically given subcutaneously in the abdomen or thigh.

If you’re new to peptide injections, see our guides on how to reconstitute peptides and how to inject peptides.

Side Effects and Safety

Tα1 has one of the cleanest safety profiles of any therapeutic peptide. Across clinical trials involving thousands of patients, adverse events have been mild and infrequent [1][3].

Common side effects:

Injection site redness or discomfort (the most frequently reported complaint)
Mild fatigue in the first few days of treatment
Occasional muscle aches

Rare side effects:

Transient fever (usually in the first week)
Skin rash

No serious adverse events have been attributed directly to Tα1 in published clinical trials. No cases of autoimmune flare have been reported, which is notable for an immune-modulating compound. The peptide does not cause immune overstimulation or cytokine storm — likely because its mechanism involves modulation rather than raw stimulation [4].

That said, anyone with an autoimmune condition should discuss Tα1 with their prescribing physician. While the data suggests it promotes immune balance rather than hyperactivation, more research is needed specifically in autoimmune populations. For a broader look at what to watch for, see our guide on peptide side effects.

Legal and Regulatory Status

Thymosin alpha-1’s regulatory journey in the U.S. has been a rollercoaster.

International approval: Zadaxin (thymalfasin) is approved as a prescription drug in over 35 countries, primarily in Asia, Latin America, Eastern Europe, and the Middle East. China and India represent the largest markets [3].

U.S. FDA status: The FDA granted orphan drug designations for hepatocellular carcinoma, malignant melanoma, DiGeorge syndrome, and chronic active hepatitis B. However, Zadaxin was never approved for general commercial sale in the U.S. [1].

Compounding access: Prior to 2024, Tα1 was widely available through U.S. compounding pharmacies. The FDA’s updated rules on compounded peptides initially placed it in Category 2 (restricted), which cut off access. However, following public comment and clinical advocacy, the FDA reclassified thymosin alpha-1 back to Category 1 in early 2026, restoring its availability through 503A compounding pharmacies [13].

For a complete breakdown of these regulatory changes, see our guide on the FDA peptide reclassification in 2026 and our overview of peptide legality.

Thymosin Alpha-1 vs Other Immune Peptides

Tα1 isn’t the only peptide with immune effects, but it occupies a distinct niche:

Peptide	Primary Mechanism	Approval Status	Route
Thymosin Alpha-1	T-cell maturation, DC activation, NK cell enhancement	Approved in 35+ countries	Subcutaneous injection
BPC-157	Anti-inflammatory, tissue repair	Not approved anywhere	SC injection or oral
LL-37	Antimicrobial, innate immunity	Research only	Topical or SC
Thymosin Beta-4 (TB-500)	Tissue repair, anti-inflammatory	Not approved anywhere	SC injection

The key distinction: Tα1 directly programs adaptive immune cells. BPC-157 and TB-500 primarily work through tissue repair and inflammation pathways. They’re complementary rather than competing compounds. Some clinicians include Tα1 in broader peptide stacks alongside recovery-focused peptides.

Explore the evidence: See all 9 Thymosin Alpha-1 studies in our research database, or browse the full peptide therapy statistics for 2026.

FAQ

Is thymosin alpha-1 FDA approved?▼

Tα1 is not FDA-approved for commercial sale in the U.S., but it holds orphan drug designations for several conditions and is approved as Zadaxin in over 35 countries. As of early 2026, it’s available in the U.S. through compounding pharmacies after being reclassified to Category 1.

How long does thymosin alpha-1 take to work?▼

Most clinical trials used treatment courses of 6 months. Immune marker improvements (T-cell counts, NK cell activity) can appear within 2–4 weeks, but clinical outcomes like viral clearance or sustained immune recovery typically take 3–6 months [6][7].

Can thymosin alpha-1 cause autoimmune reactions?▼

No autoimmune flares have been reported in published clinical trials. Tα1 modulates immune function bidirectionally — it increases activity when suppressed and promotes regulatory T-cells that prevent overactivation. However, patients with existing autoimmune conditions should consult their physician before starting treatment [4].

What is the difference between thymosin alpha-1 and thymosin beta-4?▼

They’re different peptides with different functions. Thymosin alpha-1 programs immune cells and modulates adaptive immunity. Thymosin beta-4 (TB-500) is primarily involved in tissue repair, cell migration, and wound healing. The names are similar because both were originally isolated from thymus tissue, but they work through entirely different pathways.

Do I need a prescription for thymosin alpha-1?▼

In the U.S., yes. Tα1 requires a prescription from a licensed healthcare provider and must be obtained through a compounding pharmacy. See our guide on how to get peptides prescribed or explore peptide therapy online options.

Sources

Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin α1. Expert Opinion on Biological Therapy. 2009;9(5):593-608. doi:10.1517/14712590902911412
Palmer DB. The effect of age on thymic function. Frontiers in Immunology. 2013;4:316. doi:10.3389/fimmu.2013.00316
Tuthill C, Rios I, McBeath R. Thymalfasin: preclinical and clinical data. Annals of the New York Academy of Sciences. 2010;1194:130-135. doi:10.1111/j.1749-6632.2010.05482.x
Romani L, et al. Thymosin α1: an endogenous regulator of inflammation, immunity, and tolerance. Annals of the New York Academy of Sciences. 2012;1270:45-51. doi:10.1111/j.1749-6632.2012.06797.x
Garaci E. Thymosin alpha1: a historical overview. Annals of the New York Academy of Sciences. 2007;1112:14-20. doi:10.1196/annals.1415.039
Chan HL, et al. Thymalfasin and chronic hepatitis B: a randomized controlled trial. Hepatology. 2001;33(2):466-472. doi:10.1053/jhep.2001.21713
Xue Y, et al. Thymosin alpha 1 for chronic hepatitis B: a meta-analysis of randomized controlled trials. World Journal of Gastroenterology. 2014;20(33):11614-11622. doi:10.3748/wjg.v20.i33.11614
Kullavanuaya P, et al. Pharmacokinetics and efficacy of thymosin alpha-1 combined with interferon and ribavirin in hepatitis C patients. Hepatology International. 2007;1:399-405.
Maio M, et al. Thymosin alpha 1 in cancer: a meta-analysis of randomized controlled trials. Annals of the New York Academy of Sciences. 2010;1194:143-150. doi:10.1111/j.1749-6632.2010.05488.x
Wu J, et al. Thymosin alpha 1 for severe sepsis: a meta-analysis of randomized controlled trials. Internal and Emergency Medicine. 2015;10:97-104. doi:10.1007/s11739-014-1140-4
Liu Y, et al. Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. Clinical Infectious Diseases. 2020;71(16):2150-2157. doi:10.1093/cid/ciaa583
Sun Q, et al. Thymosin alpha-1 for COVID-19: a randomized controlled trial. Critical Care. 2021;25:262. doi:10.1186/s13054-021-03684-3
U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A; Revised Proposed Rule. 2026.